TB-500 sits in a different regulatory category to almost every other compound in this buyer's guide series. It's not FDA-approved. It's not on the Category 2 list (which would at least mark it as a compound under regulatory scrutiny). It's not a scheduled substance. It's an unregulated research peptide — meaning there is no formal quality oversight of any kind on any product sold with this name, and no legal compounding pharmacy pathway to access it. Zero human clinical trials have been published on TB-500 specifically as of 2026 (WADA, 2025).
That context doesn't make TB-500 without research interest. The underlying compound — thymosin beta-4 (Tβ4) — has a Phase II cardiac surgery trial in progress and a substantial preclinical evidence base. TB-500 is a synthetic fragment of Tβ4 (the actin-sequestering region, residues 17–23). But the regulatory void means sourcing quality is entirely on the buyer to verify — there are no institutional checks in the supply chain.
Key Takeaways
- —TB-500 is unregulated — no FDA scheduling, no compounding pathway, no institutional quality oversight. Every quality check falls on the buyer.
- —Zero published human clinical trials exist for TB-500 specifically; the Phase II cardiac data is for full-length Tβ4 (Thymosin Beta-4), not the fragment.
- —TB-500 has been on the WADA Prohibited List since 2011 — any competitive athlete subject to anti-doping testing is categorically banned from use.
- —Before considering any protocol, read the TB-500 research profile on Next Pep for the full mechanism, evidence review, and dosing context.
TB-500 is a synthetic peptide corresponding to residues 17–23 of thymosin beta-4 — the actin-sequestering domain responsible for Tβ4's cell migration and tissue repair activity. Its molecular weight is approximately 889 Da and its sequence is Ac-LKKTETQ-NH₂ (in most commercial formulations). The CAS number most commonly cited for TB-500 is 77591-33-4.
This distinction from full-length Tβ4 (MW ~4,963 Da) matters for quality verification. A vendor selling "TB-500" should be selling the specific 7-amino-acid fragment at 889 Da — not a longer fragment, not the full protein. Mass spectrometry at 889 Da is the key identity confirmation.
The pharmacological rationale for using the fragment rather than the full protein comes from studies showing that the actin-sequestering domain alone replicates Tβ4's cell migration-promoting activity. The fragment is also easier and less expensive to synthesise at research scale. Whether the full-length protein would produce different or superior effects in any particular application isn't established.
Because there's no regulatory floor on TB-500 quality, third-party analytical testing is the only protection. The same verification framework that applies to all research peptides applies here — with two TB-500-specific additions.
HPLC purity ≥98%. Standard minimum for research-grade peptides. At ≥99% you're getting elite-grade material appropriate for binding and cell migration assays; 95–98% is acceptable for most preclinical work.
Mass spectrometry at ~889 Da. This is the TB-500-specific confirmation. The measured mass of the peptide should be approximately 889.04 Da (for the acetylated, amidated form). If the vendor's COA shows a different mass — particularly anything near 4,963 Da (full Tβ4) — they're mislabelling the product.
Independent lab with verifiable report ID. Not the vendor's internal testing. An accredited, named analytical laboratory, with a report number you can confirm directly on the lab's server. This eliminates the majority of low-quality vendors.
Endotoxin (LAL) assay. Because TB-500 research protocols often involve subcutaneous injection, endotoxin burden is clinically relevant. LPS contamination at research-relevant doses can cause local inflammation and systemic reactions that are unrelated to the peptide's mechanism. Ask specifically whether endotoxin testing was performed and request the result.
Lyophilised form, stored at -20°C. TB-500 in solution degrades significantly faster than the lyophilised powder form. Properly lyophilised TB-500 should be white to off-white with no yellowing. Discolouration indicates oxidation or improper processing.
Understanding TB-500's evidence base before purchasing is the most important step in the process. The compound has a compelling theoretical mechanism — actin regulation, cell migration, cardiac regeneration — and a consistent preclinical record. But the human data situation is stark.
There are zero published human clinical trials on TB-500 specifically. The Phase II cardiac trial that exists is for full-length Thymosin Beta-4, not TB-500. The two aren't the same molecule. Whether the fragment replicates the full protein's cardiac regeneration activity in humans isn't established (PMC literature, 2024). The musculoskeletal protocols in common use are extrapolated from animal studies and clinical practitioner reports, not controlled human trials.
This doesn't make the preclinical evidence meaningless — it's why TB-500 gets serious research attention. But it does mean anyone purchasing it is working from a significantly weaker evidence base than compounds like sermorelin (FDA-approved history, human IGF-1 data) or tirzepatide (FDA-approved, 72-week RCT).
The TB-500 research profile on Next Pep covers the full actin regulation mechanism, the cardiac progenitor cell data, the Tβ4 fragment vs. full protein distinction, dosing protocols derived from the Phase II trial precedent, and the honest evidence summary. That's the starting point.
WADA has prohibited TB-500 since 2011 under the Prohibited List category for peptide hormones and related substances. Detection methods have been specifically developed for TB-500 metabolites in urine and plasma (WADA scientific research, 2025). Any competitive athlete — professional or amateur — subject to anti-doping testing should treat TB-500 as categorically detectable and prohibited.
The Next Pep comparison tool lets you put TB-500 alongside BPC-157 across mechanism, half-life, and dosing data. Many practitioners combine the two compounds specifically because their mechanisms are complementary — BPC-157 drives angiogenesis while TB-500 drives cell migration. Understanding what each contributes before purchasing either is worth the twenty minutes the comparison takes. The peptide library covers both compounds in full, with molecular data, human trial summaries, and regulatory status — the objective research foundation before you evaluate any vendor. When you've settled on a protocol, the dosing calculator converts your vial mg to exact draw volume and syringe units.
No — they're related but distinct. Thymosin beta-4 (Tβ4) is the full 43-amino-acid endogenous protein (MW ~4,963 Da). TB-500 is a synthetic 7-amino-acid fragment corresponding to residues 17–23 of Tβ4 (MW ~889 Da) — specifically the actin-sequestering domain. Most published research on cardiac regeneration and tissue repair used full-length Tβ4, not the TB-500 fragment. Whether the fragment replicates all of the full protein's activities in humans isn't established.
Request the COA and confirm mass spectrometry shows approximately 889 Da. If the COA shows a MW near 4,963 Da, you're receiving full-length Tβ4 (a different compound) or the COA is mislabelled. Confirm HPLC purity ≥98%. Verify the report ID directly on the issuing lab's server. If any of these steps fail, don't purchase from that vendor.
TB-500 is not a scheduled controlled substance in the US — personal possession is not a criminal offence. It's also not FDA-approved, not on the Category 2 restricted list (which limits compounding), and not regulated as a pharmaceutical in any jurisdiction. WADA prohibits it for competitive athletes. It exists in a complete regulatory grey zone: legal to possess, unregulated in quality, prohibited in sport.
The two are frequently combined in musculoskeletal research protocols on the basis that their mechanisms are complementary — BPC-157 drives angiogenesis and GH receptor upregulation while TB-500 drives cell migration via actin regulation. No published study has examined the combination directly. There's no known contraindication. The combination hasn't been formally studied in humans under any protocol.
This article is for research and educational purposes only. TB-500 is not approved for human therapeutic use in any jurisdiction. WADA prohibits its use in competitive sport. Consult a licensed healthcare professional before considering any peptide protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.